2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | ENS | AVA | ||
| 100 | NON | AVA | ||
| 100 | NON | NON | ||
| 1 000 | NON | AVA | ||
| 21 280 | NON | AVA |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenCHOSA Oncology today presented positive data at the European Lung Cancer Congress (ELCC) 2026 for its Platin-DRP® biomarker, demonstrating improved survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy... How does AI assess today's news: It's a game-changer for CHOSA Oncology. The figures from ELCC 2026 are not just "fine" – they are extremely strong clinically. Here are the three most important reasons why this is a major breakthrough for them: Massive survival difference: A median survival of 16.9 months versus 5.5 months is an enormous difference in cancer research. Being able to identify a group that lives three times as long by using their test makes Platin-DRP® a very strong argument for both doctors and hospitals. Solves a "blind spot": Although platinum-based chemo is standard treatment, there has long been a lack of a way to know who it actually works on. CHOSA now has data showing that they can close that gap. This makes them extremely attractive for potential partnerships or acquisitions from larger pharmaceutical companies. Validation of the technology: Since the data comes from the independent SPLENDOUR study (and is presented in collaboration with significant organizations like EORTC), the results have high credibility in the scientific community. This reduces the regulatory risk towards approval. In short: The news moves CHOSA from being "a hopeful biotech company" to having concrete, statistically significant evidence that their product saves (or at least prolongs) lives.- ·1 päivä sittenRemember CHOSA presents today at the "Lung Cancer Congress" fair: CHOSA Oncology is ready to present significant data on its Platin-DRP biomarker at the European Lung Cancer Congress (ELCC) 2026 on March 26th. The presentation will detail results from a translational analysis of the Phase III SPLENDOUR study, conducted in collaboration with ETOP/EORTC. This analysis evaluates the Platin-DRP score's correlation with clinical outcomes in patients with advanced non-small cell lung cancer treated with platinum-based therapies. The company believes that Platin-DRP can be a crucial tool to predict treatment success and optimize patient selection. CHOSA Oncology will present data on its Platin-DRP biomarker for advanced non-small cell lung cancer (NSCLC) at ELCC 2026 on March 26th. The data stems from a translational analysis of the ETOP/EORTC Phase III SPLENDOUR study, which evaluates Platin-DRP's correlation with clinical outcomes in platinum-treated NSCLC patients. In a retrospective study, lung cancer patients with the top 10% Platin-DRP scores achieved a 90% 3-year survival rate, significantly higher than the 40% for the bottom 10%. Platin-DRP, a 205-gene biomarker signature, aims to identify patients who are most likely to benefit from cis- and carboplatin treatments. The company will hold an online webinar on March 26th at 5:00 PM CET to discuss the new data and the company's insights.
- ·19.3.Note it is the result of a Phase III study: The analysis is based on a Phase III study and evaluates the correlation between the biomarker and clinical outcomes when treated with platinum-based drugs. The results apply to patients with advanced non-small cell lung cancer and are presented in a poster session. Complete data will be published in connection with the presentation.
- ·19.3.Finally some news👍 On March 19, 2026, CHOSA Oncology announced today that data on their Platin-DRP biomarker in advanced non-small cell lung cancer (NSCLC) will be presented at ELCC 2026 - European Lung Cancer Congress - on Thursday, March 26. The conference will take place from March 25-28, 2026 in Copenhagen, Denmark. See in news!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenCHOSA Oncology today presented positive data at the European Lung Cancer Congress (ELCC) 2026 for its Platin-DRP® biomarker, demonstrating improved survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy... How does AI assess today's news: It's a game-changer for CHOSA Oncology. The figures from ELCC 2026 are not just "fine" – they are extremely strong clinically. Here are the three most important reasons why this is a major breakthrough for them: Massive survival difference: A median survival of 16.9 months versus 5.5 months is an enormous difference in cancer research. Being able to identify a group that lives three times as long by using their test makes Platin-DRP® a very strong argument for both doctors and hospitals. Solves a "blind spot": Although platinum-based chemo is standard treatment, there has long been a lack of a way to know who it actually works on. CHOSA now has data showing that they can close that gap. This makes them extremely attractive for potential partnerships or acquisitions from larger pharmaceutical companies. Validation of the technology: Since the data comes from the independent SPLENDOUR study (and is presented in collaboration with significant organizations like EORTC), the results have high credibility in the scientific community. This reduces the regulatory risk towards approval. In short: The news moves CHOSA from being "a hopeful biotech company" to having concrete, statistically significant evidence that their product saves (or at least prolongs) lives.
- ·1 päivä sittenRemember CHOSA presents today at the "Lung Cancer Congress" fair: CHOSA Oncology is ready to present significant data on its Platin-DRP biomarker at the European Lung Cancer Congress (ELCC) 2026 on March 26th. The presentation will detail results from a translational analysis of the Phase III SPLENDOUR study, conducted in collaboration with ETOP/EORTC. This analysis evaluates the Platin-DRP score's correlation with clinical outcomes in patients with advanced non-small cell lung cancer treated with platinum-based therapies. The company believes that Platin-DRP can be a crucial tool to predict treatment success and optimize patient selection. CHOSA Oncology will present data on its Platin-DRP biomarker for advanced non-small cell lung cancer (NSCLC) at ELCC 2026 on March 26th. The data stems from a translational analysis of the ETOP/EORTC Phase III SPLENDOUR study, which evaluates Platin-DRP's correlation with clinical outcomes in platinum-treated NSCLC patients. In a retrospective study, lung cancer patients with the top 10% Platin-DRP scores achieved a 90% 3-year survival rate, significantly higher than the 40% for the bottom 10%. Platin-DRP, a 205-gene biomarker signature, aims to identify patients who are most likely to benefit from cis- and carboplatin treatments. The company will hold an online webinar on March 26th at 5:00 PM CET to discuss the new data and the company's insights.
- ·19.3.Note it is the result of a Phase III study: The analysis is based on a Phase III study and evaluates the correlation between the biomarker and clinical outcomes when treated with platinum-based drugs. The results apply to patients with advanced non-small cell lung cancer and are presented in a poster session. Complete data will be published in connection with the presentation.
- ·19.3.Finally some news👍 On March 19, 2026, CHOSA Oncology announced today that data on their Platin-DRP biomarker in advanced non-small cell lung cancer (NSCLC) will be presented at ELCC 2026 - European Lung Cancer Congress - on Thursday, March 26. The conference will take place from March 25-28, 2026 in Copenhagen, Denmark. See in news!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | ENS | AVA | ||
| 100 | NON | AVA | ||
| 100 | NON | NON | ||
| 1 000 | NON | AVA | ||
| 21 280 | NON | AVA |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
29 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 29.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 30.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenCHOSA Oncology today presented positive data at the European Lung Cancer Congress (ELCC) 2026 for its Platin-DRP® biomarker, demonstrating improved survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy... How does AI assess today's news: It's a game-changer for CHOSA Oncology. The figures from ELCC 2026 are not just "fine" – they are extremely strong clinically. Here are the three most important reasons why this is a major breakthrough for them: Massive survival difference: A median survival of 16.9 months versus 5.5 months is an enormous difference in cancer research. Being able to identify a group that lives three times as long by using their test makes Platin-DRP® a very strong argument for both doctors and hospitals. Solves a "blind spot": Although platinum-based chemo is standard treatment, there has long been a lack of a way to know who it actually works on. CHOSA now has data showing that they can close that gap. This makes them extremely attractive for potential partnerships or acquisitions from larger pharmaceutical companies. Validation of the technology: Since the data comes from the independent SPLENDOUR study (and is presented in collaboration with significant organizations like EORTC), the results have high credibility in the scientific community. This reduces the regulatory risk towards approval. In short: The news moves CHOSA from being "a hopeful biotech company" to having concrete, statistically significant evidence that their product saves (or at least prolongs) lives.
- ·1 päivä sittenRemember CHOSA presents today at the "Lung Cancer Congress" fair: CHOSA Oncology is ready to present significant data on its Platin-DRP biomarker at the European Lung Cancer Congress (ELCC) 2026 on March 26th. The presentation will detail results from a translational analysis of the Phase III SPLENDOUR study, conducted in collaboration with ETOP/EORTC. This analysis evaluates the Platin-DRP score's correlation with clinical outcomes in patients with advanced non-small cell lung cancer treated with platinum-based therapies. The company believes that Platin-DRP can be a crucial tool to predict treatment success and optimize patient selection. CHOSA Oncology will present data on its Platin-DRP biomarker for advanced non-small cell lung cancer (NSCLC) at ELCC 2026 on March 26th. The data stems from a translational analysis of the ETOP/EORTC Phase III SPLENDOUR study, which evaluates Platin-DRP's correlation with clinical outcomes in platinum-treated NSCLC patients. In a retrospective study, lung cancer patients with the top 10% Platin-DRP scores achieved a 90% 3-year survival rate, significantly higher than the 40% for the bottom 10%. Platin-DRP, a 205-gene biomarker signature, aims to identify patients who are most likely to benefit from cis- and carboplatin treatments. The company will hold an online webinar on March 26th at 5:00 PM CET to discuss the new data and the company's insights.
- ·19.3.Note it is the result of a Phase III study: The analysis is based on a Phase III study and evaluates the correlation between the biomarker and clinical outcomes when treated with platinum-based drugs. The results apply to patients with advanced non-small cell lung cancer and are presented in a poster session. Complete data will be published in connection with the presentation.
- ·19.3.Finally some news👍 On March 19, 2026, CHOSA Oncology announced today that data on their Platin-DRP biomarker in advanced non-small cell lung cancer (NSCLC) will be presented at ELCC 2026 - European Lung Cancer Congress - on Thursday, March 26. The conference will take place from March 25-28, 2026 in Copenhagen, Denmark. See in news!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 380 | ENS | AVA | ||
| 100 | NON | AVA | ||
| 100 | NON | NON | ||
| 1 000 | NON | AVA | ||
| 21 280 | NON | AVA |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 5 | 51 480 | −51 475 | 0 |
| Danske Bank A/S | 0 | 8 103 | −8 103 | 0 |
| Skandinaviska Enskilda Banken AB | 380 | 0 | +380 | 0 |
| Svenska Handelsbanken AB | 1 000 | 0 | +1 000 | 0 |
| SSW Market Making GmbH | 28 720 | 6 000 | +22 720 | 0 |
| Nordnet Bank AB | 35 578 | 100 | +35 478 | 100 |